Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Non-Alcoholic Fatty Liver Disease Clinical Trials

101 recruiting trials for Non-Alcoholic Fatty Liver Disease. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
101
Total Trials
101
Recruiting Now
6
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT06588699

Digoxin In NASH (CODIN)

Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was...

Sponsor: Yale UniversityEnrolling: 1442 locations
RECRUITINGNCT04496895

The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults

To assess whether orange peel fermentation has the effect of reducing body fat in adults

Sponsor: TCI Co., Ltd.Enrolling: 1241 location
RECRUITINGEarly Phase 1NCT07185932

Efficacy and Safety of Rifaximin in Treating MAFLD

Study Objective: to evaluate the efficacy and safety of rifaximin in the treatment of metabolic-associated fatty liver disease (MAFLD), and investigate the underlying mechanisms...

Sponsor: Shanghai Changzheng HospitalEnrolling: 401 location
RECRUITINGNCT04365855

The Olmsted NAFLD Epidemiology Study (TONES)

Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized...

Sponsor: Mayo ClinicEnrolling: 8001 location
RECRUITINGNCT06211556

Depletion of Liver Fat in Type 2 Diabetes

The aim of this randomized trial is to determine whether liver fat depletion via a short-term (i.e., two weeks) very-low calorie diet will restore the normal exercise-induced...

Sponsor: Rigshospitalet, DenmarkEnrolling: 421 location
RECRUITINGNCT06329544

High Fructose Diet, the Gut Microbiome, and Metabolic Health

Americans commonly consume excess amounts of dietary fructose. Added fructose has been shown to have an adverse impact on metabolic health, including increased insulin resistance...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 301 location
RECRUITINGPhase 2NCT05519475

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic...

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have metabolic dysfunction-associated...

Sponsor: Regeneron PharmaceuticalsEnrolling: 9020 locations
RECRUITINGNCT06503068

Impact of NAFLD vs MAFLD Stigma on Quality of Life in Egyptian Patients

Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of liver disease worldwide. The global burden of NAFLD is about 30% of the population, With a higher...

Sponsor: Tanta UniversityEnrolling: 5001 location
RECRUITINGPhase 2NCT05526144

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, which is rapidly becoming a worldwide public health problem. It is more common in...

Sponsor: VA Office of Research and DevelopmentEnrolling: 1281 location
RECRUITINGPhase 3NCT06528314

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

Sponsor: Akero Therapeutics, IncEnrolling: 115020 locations
RECRUITINGNCT06704321

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content,...

Sponsor: ValbiotisEnrolling: 701 location
RECRUITINGPhase 2NCT04697810

Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks....

Sponsor: Can-Fite BioPharmaEnrolling: 11420 locations
RECRUITINGPhase 2NCT06569524

Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With...

A randomized, double-blind, placebo-controlled Phase II study,to evaluate the efficacy and safety of TQA2225/AP025 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Enrolling: 12020 locations
RECRUITINGNCT05330923

Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease

Identifying patients at risk of NAFLD(Nonalcoholic fatty liver disease), especially severe disease with NASH(nonalcoholic steatohepatitis) and fibrosis, is critical. Prevalence of...

Sponsor: Peking Union Medical College HospitalEnrolling: 2001 location
RECRUITINGNCT05332613

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30...

Sponsor: Weill Medical College of Cornell UniversityEnrolling: 401 location
RECRUITINGNCT06649162

A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical...

The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical...

Sponsor: Boryung Pharmaceutical Co., LtdEnrolling: 100002 locations
RECRUITINGNCT06396871

Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases

The goal of this cross-sectional observational study is to to perform a thorough characterization of the quantitative and qualitative differences in peripheral blood cells, and...

Sponsor: Technische Universität DresdenEnrolling: 1801 location
RECRUITINGNCT03190538

Nonalcoholic Steatohepatitis in Chinese Children

Nonalcoholic steatohepatitis (NASH) is now recognised as an increasing clinical problem in children. Steatosis without significant liver cell injury or fibrosis is the most common...

Sponsor: Humanity and Health Research CentreEnrolling: 4001 location
RECRUITINGNCT06819917

Identification of Liver Fibrosis Biomarkers

Chronic liver disease (CLD) is a major cause of global mortality and morbidity . CLD patients are at an increased risk of developing liver fibrosis (formation of scar tissue),...

Sponsor: Roche Diagnostics GmbHEnrolling: 5752 locations
RECRUITINGNCT06523179

Evaluation of Risk of hEpatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common solid cancer and the second cause of cancer-related mortality worldwide. Nonalcoholic fatty liver disease (NAFLD), that is...

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoEnrolling: 5001 location
RECRUITINGNCT06061042

Effect of Timed-Restricted Eating on Metabolic Health

We aim to determine the effect of combined isocaloric time restricted eating and meal timing on metabolic health, liver fat, functional brain networks, inflammation, and sleep...

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Enrolling: 301 location
RECRUITINGNCT06975579

The COherence of Scatter Identification and Exclusion Algorithm Study

Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040. NAFLD is an...

Sponsor: Institute of Cancer Research, United KingdomEnrolling: 151 location
RECRUITINGNCT06856252

Human Liver ORganoids as a Model to Study the Development of Non-Alcoholic SteatOhepatitis (NASH)

The primary objective of the study is to generate and characterize three-dimensional models, called "assembloids", composed of the main liver cell populations (in particular from...

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoEnrolling: 601 location
RECRUITINGPhase 4NCT07272343

The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted...

Sponsor: Second Affiliated Hospital of Nanchang UniversityEnrolling: 1001 location
RECRUITINGNCT06888310

Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is responsible for a significant proportion of liver-related deaths and healthcare costs in the United States, accounting for...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 4081 location
RECRUITINGPhase 3NCT06461208

A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis

A feasibility trial called PROFIT has previously shown that FMT administered endoscopically into the jejunum in patients with cirrhosis is safe and feasible and have identified...

Sponsor: King's College LondonEnrolling: 30020 locations
RECRUITINGPhase 1NCT06836609

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or...

This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated...

Sponsor: Regeneron PharmaceuticalsEnrolling: 1322 locations
RECRUITINGNCT05962190

Short-term Fat Overfeeding on the Effects of Liver Metabolism

Despite work showing the overconsumption of saturated fatty acids (SFA) to be metabolically deleterious, debate continues about whether there is a link between SFA and...

Sponsor: University of OxfordEnrolling: 261 location
RECRUITINGNCT05275608

Effects of VLCKD in Metabolic Syndrome

VLCKD has showed to be an impactful diet on several metabolism aspects and has proven to be useful for preventing and treating diabetes mellitus type 2, overweight, chronic...

Sponsor: Azienda Ospedaliero Universitaria Maggiore della CaritaEnrolling: 401 location
RECRUITINGNCT03542578

Diagnosis of Fatty Liver With Outpatient Ultrasound

This study will evaluate whether ultrasound performed during outpatient visit is effective in early diagnosis of fatty liver.

Sponsor: Medical College of WisconsinEnrolling: 5001 location
RECRUITINGPhase 2NCT07198386

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)

The goal of this clinical trial is to learn if CS060380 tablets works to treat non-alcoholic steatohepatitis(NASH) in adults.It will also learn about the safety of CS060380...

Sponsor: Cascade Pharmaceuticals, IncEnrolling: 1208 locations
RECRUITINGNCT06389851

Effects of Tomato Consumption on Steatosis, Intestinal Function and Glucose and Lipid Metabolism in Subjects With NAFLD

The study in question is an interventional study with nutritional intervention. the aim of the study is to evaluate whether a diet enriched with tomatoes can have favorable...

Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisEnrolling: 601 location
RECRUITINGNCT06883578

Effect of Low Valine Diet on Body Weight and Metabolic Parameters

This study aimed to explore the effects of ordinary meal replacements and low-valine meal replacements on the weight and risk of related metabolic diseases in overweight/obese...

Sponsor: Shanghai Zhongshan HospitalEnrolling: 481 location
RECRUITINGNCT07321925

Thermoacoustic Method for Estimating Liver Fat Fraction

The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard MRI PDFF...

Sponsor: Endra LifesciencesEnrolling: 491 location
RECRUITINGNCT03875625

Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention

The study is aimed * To quantify the change of adipose tissues, triglyceride in liver and pancreas and cholesterol after lifestyle intervention or bariatric surgery. * To test...

Sponsor: Chinese University of Hong KongEnrolling: 801 location
RECRUITINGNCT06619808

Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases

The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main...

Sponsor: Jinling Hospital, ChinaEnrolling: 1501 location
RECRUITINGNCT04666402

Integrated Diagnostics for Early Diagnosis of Liver Disease

This is an observational study that will explore the hypothesis that by combining data from patients with liver disease with novel blood biomarkers, single nucleotide polymorphism...

Sponsor: Manchester University NHS Foundation TrustEnrolling: 12001 location
RECRUITINGPhase 1 / Phase 2NCT07053488

CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection

This early-phase clinical trial will assess the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to reduce immunogenicity before transplantation. Donor livers will...

Sponsor: AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLCEnrolling: 901 location
RECRUITINGPhase 2NCT05821010

Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis

The goal of this clinical trial is to investigate the therapeutic potential of A. soehngenii and pasteurized A. muciniphila combined with B. animalis subsp. lactis and...

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Enrolling: 481 location
RECRUITINGNCT06939569

An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are currently of unknown etiology and incurable. In recent years, the incidence of IBD has...

Sponsor: Shanghai East HospitalEnrolling: 3371 location
RECRUITINGPhase 1 / Phase 2NCT05692024

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who...

Sponsor: Massachusetts General HospitalEnrolling: 801 location
RECRUITINGPhase 2NCT06939816

Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

This study is designed to establish the effect of 2 doses of vonafexor on the kidney. This will be investigated in subjects with mild or moderate reduced estimated glomerular...

Sponsor: Enyo PharmaEnrolling: 601 location
RECRUITINGNCT03308916

Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced...

Sponsor: Maja ThieleEnrolling: 65001 location
RECRUITINGPhase 2NCT05632861

HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)

This study will evaluate the efficacy and safety and the best effective dose of HuHuangLianzonggan capsule in subjects with nonalcoholic steatohepatitis.

Sponsor: Tasly Pharmaceutical Group Co., LtdEnrolling: 7620 locations
RECRUITINGNCT06566105

The Liver BIoBank Lombardia of Fatty Liver

NAFLD is most frequently linked to excess adiposity, insulin resistance and cardiometabolic risk factors, it has become the leading cause of liver disease worldwide, and is...

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoEnrolling: 25001 location
RECRUITINGPhase 3NCT07221188

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known...

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

Sponsor: GlaxoSmithKlineEnrolling: 12506 locations
RECRUITINGNCT07192159

Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD

This multicenter prospective study aims to evaluate the correlation between quantitative ultrasound fat fraction (USFF) and MRI-PDFF (Proton Density Fat Fraction) for liver fat...

Sponsor: Seoul National University HospitalEnrolling: 622 locations
RECRUITINGNCT03481829

Early Tracking of Childhood Health Determinants (ETCHED) Study

Background: Children s weight has increased sharply in recent years. This may put them at higher risk for health problems. High blood glucose in a pregnant mother and too much...

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrolling: 15001 location
RECRUITINGPhase 1NCT07335198

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as...

This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of...

Sponsor: GlaxoSmithKlineEnrolling: 301 location
RECRUITINGNCT06739330

Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease

This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.

Sponsor: Tanta UniversityEnrolling: 1501 location

Showing 50 of 101 trials.Search all Non-Alcoholic Fatty Liver Disease trials

Frequently Asked Questions

There are currently 101 clinical trials for Non-Alcoholic Fatty Liver Disease, with 101 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Non-Alcoholic Fatty Liver Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 6 Phase 3 trials for Non-Alcoholic Fatty Liver Disease, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.